Perspectives by the Leerink Center for Pharmacoeconomics

Epizodes

• What’s Behind Drug Pricing: The Hidden Role and Limits of Cost-Effectiveness Analysis 02.06.2026 39min

  In this episode of Perspectives by the Leerink Center for Pharmacoeconomics, Melanie Whittington breaks down a fundamental—and increasingly consequential—question in health economics: what counts as value in cost-effectiveness analysis? For biotech leaders and investors, Mel cautions that this isn’t just an academic debate. The frameworks adopted by HTA bodies influence pricing, access, and ultimately, how innovation is rewarded. In this episode, Mel explores: The evolution of perspective in cost-effectiveness analysis Why CEA is not a “precise” science—and why that matters How modeling choices impact pricing determinations And how innovators can use these tools to tell their value story
• Welcome to Perspectives by the Leerink Center for Pharmacoeconomics 29.05.2026

  In our signature podcast series, Dr. Mel Whittington, a health economist and Head of the Leerink Center for Pharmacoeconomics, talks with people from across the industry to hear their stories and to better understand the societal impact of healthcare innovations. If you’re interested in participating in future podcasts or would like to learn more about the Leerink Center for Pharmacoeconomics, please email cpe@medacorp.com.